GleamWall
中文EN

DYN Dyne Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1818794 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-42.7%
TTM EPS YoY0.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-74.6%
ROA-57.6%
ROIC (approx.)-225.2%
Asset turnover—

Leverage & solvency

Liabilities / assets24.6%
Debt / equity0.21x
Current ratio12.99x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.93x
Accruals ratio-3.8%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue————————
R&D expense$161.74M$152.17M$100.89M$95.43M$97.22M$99.24M$106.45M$81.81M
SG&A expense$35.33M$29.49M$24.39M$20.70M$16.67M$16.55M$15.93M$15.30M
Operating income-$197.07M-$181.66M-$125.28M-$116.13M-$113.89M-$115.79M-$122.37M-$97.11M
Interest expense————$2.90M$94,000——
Net income-$193.55M-$178.56M-$120.85M-$111.95M-$108.04M-$110.86M-$115.36M-$89.54M
EBITDA-$196.47M-$181.06M-$124.73M-$115.61M-$113.39M-$115.29M-$121.87M-$96.66M
EPS (basic)-1.06-1.08-0.73—-0.76-0.97-1.05—
EPS (diluted)-1.06-1.08-0.73—-0.76-0.97-1.05—
Balance sheet
Cash & equivalents$913.20M$676.11M$753.10M$893.37M$573.61M$485.04M$472.25M$435.45M
Short-term investments$221.18M$222.36M$219.05M$217.19M$218.28M$198.88M$205.24M$206.82M
Current assets$1.18B$937.89M$1.02B$1.13B$806.26M$697.95M$689.50M$659.28M
PP&E, net$7.14M$24.56M$23.68M$24.03M$23.97M$5.67M$5.75M$5.40M
Total assets$1.23B$994.01M$1.08B$1.19B$867.06M$728.99M$721.07M$691.23M
Current liabilities$90.55M$78.03M$51.25M$50.62M$59.85M$41.47M$33.88M$42.26M
Long-term debt$200.01M$199.33M$149.38M$148.92M$99.15M$98.81M—$0
Total debt$200.01M$199.33M$149.38M$148.92M$99.15M$98.81M—$0
Total liabilities$303.87M$291.86M$214.90M$214.83M$175.28M$157.55M$52.10M$61.40M
Shareholders' equity$930.93M$702.15M$865.05M$972.13M$691.78M$571.45M$668.97M$629.84M
Net debt-$713.19M-$476.79M-$603.73M-$744.45M-$474.46M-$386.23M—-$435.45M
Shares outstanding187.33M165.67M165.20M164.95M142.61M114.34M113.63M102.32M
Cash flow statement
Operating cash flow-$177.49M-$130.29M-$144.92M-$111.83M-$90.78M-$94.70M-$105.89M-$84.33M
Capital expenditure$2.01M$1.51M$221,000$484,000$395,000$60,000$981,000$1.07M
Free cash flow-$179.50M-$131.80M-$145.14M-$112.32M-$91.17M-$94.76M-$106.87M-$85.41M
Investing cash flow-$1.29M-$4.79M-$2.39M$982,000-$37.97M$6.77M$1.46M-$16.01M
Financing cash flow$418.10M$58.11M$7.06M$430.96M$217.33M$100.77M$141.24M$3.64M
Depreciation & amortization$600,000$600,000$550,000$521,000$500,000$500,000$502,000$450,000
Stock-based compensation$16.21M$14.98M$13.08M$11.23M$11.08M$10.52M$13.02M$10.48M

Free plan shows the latest 8 periods; Pro shows all 31 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.